Welcome to our dedicated page for Innate Pharma Sa SEC filings (Ticker: IPHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma S.A. reports its capital and voting structure as of December 31, 2025. The Company had 93,719,323 ordinary shares outstanding, along with 6,324 Preferred Shares 2016 and 7,581 Preferred Shares 2017. Based on French market rules, Innate calculates a total of 94,484,443 theoretical voting rights, which includes all shares with attached voting rights, even those suspended, and incorporates voting rights from AGAP 2016. The number of exercisable voting rights, which excludes treasury shares with suspended rights, was 94,465,868. The Company also highlights its focus on developing next-generation immunotherapies for cancer and notes collaborations with major partners such as AstraZeneca and Sanofi.
Innate Pharma S.A. furnished a Form 6-K as a foreign private issuer, providing its H1 2025 Half-Year Financial Report for the period from January 1 to June 30, 2025. The half-year report is attached as Exhibit 99.2 and contains the company’s detailed financial and operating information.
The company states that this Form 6-K and Exhibit 99.2 (excluding the statutory auditors' review report on page 49) are incorporated by reference into its existing registration statements on Form F-3 and Form S-8, meaning the half-year information becomes part of those U.S. securities offering documents.